TP53 Mutation Characteristics and Their Effects on Overall Survival in AML and MDS

被引：0
|
作者：
Puzo, Christian [1 ]
Hager, Karl [1 ]
Rinder, Henry [1 ]
Weinberg, Olga [2 ]
Siddon, Alexa [1 ]
机构：
[1] Yale Sch Med, New Haven, CT USA
[2] UT Southwestern Med Ctr, Dallas, TX USA
来源：
LABORATORY INVESTIGATION | 2024年 / 104卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
1180
引用
收藏
页码：S1468 / S1470
页数：3
相关论文
共 50 条
  • [31] The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
    Leroy, Bernard
    Fournier, Jean Louis
    Ishioka, Chikashi
    Monti, Paola
    Inga, Alberto
    Fronza, Gilberto
    Soussi, Thierry
    NUCLEIC ACIDS RESEARCH, 2013, 41 (D1) : D962 - D969
  • [32] IMPACT OF TP53 MUTATION ON OUTCOME OF MDS PATIENTS UNDERGOING ALLOGENEIC TRASPLANT
    Diez Campelo, M.
    Caballero, J. C.
    del Rey, M.
    Janusz, K.
    Lumbreras, E.
    Abaigar, M.
    Robledo, C.
    Jerez, A.
    Valcarcel, D.
    Calderon-Cabrera, C.
    Hernandez-Rivas, J. M.
    del Canizo, M. C.
    HAEMATOLOGICA, 2014, 99 : 348 - 348
  • [33] Effect of TP53 mutation status on survival in the MAGIC trial
    Smyth, Elizabeth Catherine
    Wilson, Sanna Hulkki
    Nankivell, Matthew Guy
    de Castro, David Gonzalez
    Wotherspoon, Andrew
    Okines, Alicia Frances Clare
    Langley, Ruth E.
    Stenning, Sally Patricia
    Cunningham, David
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [34] TP53 mutation and survival in aggressive B cell lymphoma
    Zenz, Thorsten
    Kreuz, Markus
    Fuge, Maxi
    Klapper, Wolfram
    Horn, Heike
    Staiger, Annette M.
    Winter, Doris
    Helfrich, Hanne
    Huellein, Jennifer
    Hansmann, Martin-Leo
    Stein, Harald
    Feller, Alfred
    Moeller, Peter
    Schmitz, Norbert
    Truemper, Lorenz
    Loeffler, Markus
    Siebert, Reiner
    Rosenwald, Andreas
    Ott, German
    Pfreundschuh, Michael
    Stilgenbauer, Stephan
    INTERNATIONAL JOURNAL OF CANCER, 2017, 141 (07) : 1381 - 1388
  • [35] Allo-HSCT in Treatment of TP53 Mutation-Related MDS/AML in Pediatric Patients - Report of Two Cases
    Deregowski, Maksymilian
    Deregowska, Paulina
    Sobkowiak-Sobierajska, Agnieszka
    Wachowiak, Jacek
    BONE MARROW TRANSPLANTATION, 2021, 56 (SUPPL 1) : 321 - 322
  • [36] TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML
    Weinberg, Olga K.
    Siddon, Alexa
    Madanat, Yazan F.
    Gagan, Jeffrey
    Arber, Daniel A.
    Dal Cin, Paola
    Narayanan, Damodaran
    Ouseph, Madhu M.
    Kurzer, Jason H.
    Hasserjian, Robert P.
    BLOOD ADVANCES, 2022, 6 (09) : 2847 - 2853
  • [37] Smoking and Its Prognostic Effect on Survival in Patients with TP53 Mutated MDS
    Reilly, Sean Patrick
    Bi, Xia
    French, Zachary
    Wilde, Lindsay
    Palmisiano, Neil
    BLOOD, 2022, 140 : 12339 - 12340
  • [38] TP53 mutations and MDS - not as easy as it seems
    Haase, D.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 7 - 8
  • [39] REMISSION OF AML IN A PATIENT WITH GERMLINE TP53 MUTATION AFTER DECITABINE MONOTHERAPY
    Sadanand, Arhanti
    Qayed, Muna
    Keller, Frank
    PEDIATRIC BLOOD & CANCER, 2022, 69
  • [40] TP53 Action and the Consequences of TP53 Mutation in Acute Myeloid Leukemia
    Lowe, Scott W.
    BLOOD, 2019, 134
12345